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Abstract 
Background: Bone Morphogenetic Protein 2 (BMP- 2) belongs to the 
TGF-β superfamily of proteins and plays an important role in the 
development of bone and cartilage. BMP- 2 is also associated with 
maintenance and repair of damaged bone. Recombinant human bone 
morphogenetic protein 2 (rhBMP- 2) is now produced by genetic 
engineering techniques and used in treatment of thin bone fractures in 
the jaw and spine. In this study we aimed to extract and amplify the 
BMP- 2 gene from human osteoblast cell line MG-63, insert the 
amplified BMP- 2 gene into pGEM-b1 cloning vector, and then 
transform the recombinant vector into the E.coli strain of Rosetta. This 
technique can be used in future research and BMP- 2 expression. 
Methods: After culturing MG-63 cells, approximately 5 million viable 
cells were used for extraction of Total RNA. The extracted RNA was 
used for cDNA synthesis in RT-PCR reaction. Then, the BMP- 2 gene 
was amplified by specific primers and the PCR product was cloned in 
the pGEM-b1 vector. Chemically competent E.coli cells were prepared 
using CaCl2 0.1 M and transformed with recombinant pGEM-b1 
vector under heat shock. The transformed E.coli Rosetta bacteria were 
inoculated on LB agar medium containing Ampicillin. Bacterial colony 
containing recombinant vector was isolated and used for plasmid 
extraction. The extracted plasmid was used for specific PCR to confirm 
the presence of BMP- 2 gene in pGEM- b1 vector. 
Results: After transformation, the E.coli Rosetta had the ability to 
become resistant to ampicillin and could grow on ampicillin- 
containing medium. While non-transformed E.coli Rosetta could not 
grow on LB agar containing ampicillin. The 1100 bp fragment was 
obtained from PCR amplification with specific primers, indicating that 
the BMP- 2 gene was inserted into pGEM-b1 vector. 
Conclusions: The pGEM-b1 vector and E.coli Rosetta strain were not 
used for BMP- 2 cloning in previous investigations. Therefore, this 
method may be a useful approach to reduce the challenges ahead of the 
optimization of BMP- 2 production. 
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Introduction 
Ossification or osteogenesis is a process that begins with the 
migration and mitosis of mesenchymal stem cells (MSCs), 
continues with the differentiation of MSCs into osteoprogenitor 
cells, and completes with the maturation of bone progenitor cells 
into osteocytes. Many growth factors are involved in the 
generation and repair of bone and other connective tissues. These 
growth factors are classified according to their biological activity 
into several families: insulin-like growth factors, platelet-derived 
growth factor, fibroblast growth factors, epidermal growth factor 
(EGF), and transforming growth factor β (TGF-β).1,2 
Bone morphogenetic proteins (BMPs) are members of the 
TGF-β superfamily and are known as multifunctional cytokines. 
These proteins can induce the formation of new bone and 
cartilage and play a central role in the maintenance and repair of 
damaged bone. More than 20 different BMPs have been identified 
and sub-classified according to the similarities of their function 
and amino acid sequences.3 Bone morphogenetic protein-2 (BMP-
2), which is a member of the BMP subgroup of TGF-β 
superfamily, was demonstrated to play a key role in bone 
generation and is involved in the hedgehog pathway, TGF-β 
signaling pathway, cytokine–cytokine receptor interaction, cardiac 
muscle cells differentiation, and the epithelial-mesenchymal 
transition phenomenon.4 
Currently, BMPs are produced by recombinant DNA 
technology and are used in dentistry, oral and maxillofacial 
surgery, and orthopedic applications. In fact, BMP molecules 
have been synthesized through recombinant DNA technology and 
have been imported into the desired location (e.g., into the broken 
bone). BMPs activate the cell signaling pathways in MSCs and 
cause stem cell migration toward the injured area, thereby 
allowing MSC differentiation into osteoblasts to participate in 
bone fracture healing. BMP-2 and BMP-7 are known as 
osteoinductive proteins and are capable of inducing the osteoblast 
differentiation. Therefore, the expression and purification of 
BMP-2 and BMP-7 in various expression systems are greatly 
regarded, and recombinant human BMP-2 and -7 (rhBMP-2 and 
rhBMP-7) have been approved by the FDA.5 
BMPs have been expressed using various protein expression 
vectors and hosts, such as Escherichia coli, Pichia pastoris, 
Baculovirus/insect cells, and mammalian cell lines.6-8 To develop 
research in the field of rhBMP-2 production for clinical use, we 
decided to use the pGEM-b1 vector and E. coli Rosetta strain as a 
new vector–host expression system. In this study, we aimed to 
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extract and amplify the BMP-2 gene from human osteosarcoma 
cell line MG-63, insert the amplified BMP-2 gene into the pGEM-
b1 cloning vector, and then transform the recombinant vector into 
the E. coli Rosetta strain. This technique may improve the 
expression of recombinant BMP-2 in the future. 
Materials and Methods  
The human osteosarcoma cell line MG-63 was obtained from 
the Pasteur Institute of Iran. The MG-63 cells were cultured in 
Dulbecco’s modified Eagle’s medium-high glucose supplemented 
with 10% fetal bovine serum and 2% pen–strep (final 
concentrations: 10-units/ml penicillin G, 10-g/ml streptomycin). 
Cells were cultured in a humidified incubator at 37°C, using a 
standard mixture of 95% air and 5% CO2. For passaging, cells 
were detached with trypsin/EDTA and subsequently replated. 
Total RNA was extracted from 5 million viable MG-63 cells 
using a GF-1 Total RNA Extraction Kit (Vivantis Technologies, 
Malaysia), according to the manufacturer’s protocol. The ratio of 
absorbance at 260-nm and 280-nm wavelength was used to assess 
the purity of extracted RNA. 
First-strand cDNA was synthesized using the Viva 2-steps 
RT-PCR kit (Vivantis Technologies, Malaysia). In the first step, a 
mixture of 10-µg RNA, 1-µl random hexamer primer (50 ng/µl), 
and 1-µl dNTP mix (10 mM) was prepared in 10-µl DEPC water 
and incubated at 65°C for 5 min and chilled on ice for 2 min. In 
the second step, a mixture of 2-µl 10× buffer M-MuLV and 100 
units of M-MuLV reverse transcriptase was prepared in 10-µl 
DEPC water and added to the first mixture. This was then 
incubated at 42°C for 60 min. The reactions were further 
incubated at 85°C for 5 min to terminate the reaction. 
Specific primers for the BMP-2 gene were designed using 
Gene Runner software, and the restriction sites of SalI and KpnI 
enzymes were embedded at the 5′ end of forward and reverse 
primers, respectively. The primer pairs were synthesized by 
SinaClon BioScience co., Iran. The BMP-2 primer sequences are 
shown in Table 1. 
A PCR amplification mixture was prepared in a final volume 
of 30 µl containing 5-µl cDNA, 3-µl 10× buffer, 1.5 mM MgCl2, 
0.8 mM dNTP, 0.5 µM of each primer, 1 U Taq DNA 
polymerase, and water up to 30 µl. The thermal cycler (primus, 
Germany) was programmed for incubation at 94°C for 2 min, 35 
cycles with denaturation at 94°C for 30 s, annealing at 57°C for 
30 s, extension at 72°C for 45 s, and final extension at 72°C for 7 
min. To check the PCR reaction, 5-µl PCR product was mixed 
with 6× DNA loading dye and loaded onto 1.5% agarose gel. 
After the electrophoresis (100 V for 50 min), the gel was stained 
with ethidium bromide (0.5 µg/ml) and the amplicon was 
visualized using a UV trans-illuminator (Uvitec, UK). The 
remaining 25-µl PCR product was purified using the AmbiClean 
Kit (Vivantis Technologies, Malaysia) and subsequently digested 
using SalI and KpnI restriction enzymes (Thermo Scientific, 
USA): 3-µl Tango buffer 10× (Thermo Scientific, USA) and 1 µl 
of each restriction enzyme was added to purify the PCR product, 
and the mixture was incubated at 37°C for 3 h.  
The pGEM-b1 vector was also double digested using SalI and 
KpnI restriction enzymes (Thermo Scientific, USA): 3-µl Tango 
buffer 10× (Thermo Scientific, USA) and 1 µl of each restriction 
enzyme was added to 200–500-ng plasmid, and the mixture was 
incubated at 37°C for 3 h. The digested pGEM-b1 vector was 
electrophoresed in 1% agarose gel. The target band was cut and 
linearized pGEM-b was extracted from agarose gel according to 
the instructions for the GF-1 Gel DNA Recovery Kit (Vivantis 
Technologies, Malaysia). 
The recombinant pGEM-b1 vector containing the BMP-2 
gene was generated by mixing 60-ng BMP-2 PCR product, 30-ng 
linearized pGEM-b1 vector, 1-µl 10× ligation buffer, 2 U of T4 
DNA ligase (Thermo Scientific, USA), and water up to 10 µl. The 
ligation mixture was incubated overnight at 16°C. 
E. coli Rosetta cells were grown overnight in 5-ml LB broth. 
The next day, 150-µl overnight culture (OD 600 = 1.2) was 
transferred to 10-ml LB broth and incubated at 37°C for 2 h with 
shaking (180 rpm). The bacterial cells (OD 600 = 0.6) were 
collected by centrifuging at 4500 rpm (4°C) for 15 min. The cell 
pellet was resuspended in 5-ml ice-cold 0.1 M CaCl2 and placed 
on ice for 30 min. The bacterial pellets were collected again by 
centrifugation at 4500 rpm for 15 min. The process was repeated 
once with 2.5-ml ice-cold 0.1 M CaCl2. Finally, the cell pellet 
was resuspended in 100-µl ice-cold 0.1 M CaCl2 and transferred 
to a 1.5-ml Eppendorf tube. Next, 6-µl ligation reaction was added 
to competent cells and placed on ice for 30 min. The recombinant 
pGEM-b1 vector was transformed into E. coli Rosetta by heat 
shock at 42°C for 2 min and immediately placed on ice for 5 min. 
Subsequently, 800-µl LB broth was added to an Eppendorf tube 
and incubated at 37°C for 1 h. Finally, the cells were spread on an 
LB agar plate with 100-µg ampicillin and incubated at 37°C. 
Single colonies were picked from the LB agar plate 
containing 100-µg ampicillin after incubation at 37°C overnight. 
Colonies were then inoculated into 5–10-ml LB broth containing 
ampicillin and incubated at 37°C for 16–18 h with shaking. The 
pGEM-b1 vector was extracted from the bacterial culture using a 
GF-1 Plasmid Extraction Kit (Vivantis Technologies, Malaysia) 
according to the manufacturer’s protocol and the presence of 
extracted plasmid was checked on a 1.5% agarose gel. 
PCR amplification with specific primers (Table 1) was 
performed to confirm the presence of the BMP-2 gene in the 
pGEM-b1 vector. PCR mixture was prepared in a final volume of 
30 µl containing 30-ng recombinant pGEM-b1 vector, 15-µl Taq 
DNA polymerase 2× Master Mix (Ampliqon, Denmark), 0.5 µM 
of each primer, and water up to 30 µl. The thermocycler program 
was the same as the BMP-2 amplification using cDNA. Agarose 
gel electrophoresis was performed by loading 5-µl PCR product 
into 1.5% agarose gel. The gel was run at 100 V for 50 min and 
stained with ethidium bromide solution. The amplicon was 
visualized using UV trans-illuminator (Uvitec, UK). 
Results 
In this study, we used the pGEM-b1 vector, which is a 
cloning vector with an ampicillin resistance marker. After 
transformation, the E. coli Rosetta has the ability to become 
resistant to ampicillin and can grow on an ampicillin-containing 
medium, whereas non-transformed E. coli Rosetta cannot grow on 
LB agar containing ampicillin.  
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Table 1. BMP-2 specific primers 
%GC Tm Sequence  Restriction enzymes sites BMP-2 primers 
60 % 64.8 °C ATAAGCGACGCAGTTCCGCAGCTGG SalI Forward 
56 % 62.7 °C ATAAGGTACCGCGACACCCACAACC KpnI Reverse 
 
 
 
 
 
 
The recombinant pGEM-b1 vector containing the BMP-2 
gene was extracted from an overnight culture of transformed E. 
coli Rosetta, and BMP-2 gene was amplified using specific 
primers. The 1100-bp fragment was obtained by PCR 
amplification with specific primers, indicating that the BMP- 2 
gene is inserted into a pGEM-b1 vector (Figure 1). 
 
 
Figure 1. PCR product of BMP-2 gene amplification. Lane 1: negative control, 
Lane 2: Test, Lane 3: DNA ladder 1Kb (250- 10000 bp) 
Discussion 
Since the identification of BMPs in 1965, extensive studies 
have been performed on bone healing. Particularly, BMP-2, as a 
member of TGF-β superfamily and a regulator of bone 
regeneration, has been widely investigated. Kunikazu et al., 
(2006) showed that BMP-2 can act as an initiator of endogenous 
bone repair and that mice lacking the ability to produce BMP-2 in 
their bones have spontaneous fractures. The results of their study 
demonstrated that BMP-2 is a necessary component of the 
signaling cascade that governs fracture repair. Although other 
osteogenic stimuli are present in the limb skeleton of BMP-2 
deficient mice, they are not able to repair damaged bone.9 
Tian et al., (2009) designed a bicistronic vector containing 
BMP-2 and vascular endothelial growth factor (VEGF)-165 
genes. VEGF is an important mediator of angiogenesis that plays 
a key role in bone growth through the endochondral ossification 
pathway. This bicistronic vector has been used to investigate the 
interaction between BMP-2 and VEGF in bone formation. The 
results of this study indicated that BMP-2 and VEGF have a 
synergistic effect on bone regeneration.10 
A large amount of BMP-2 is needed for both bone tissue 
engineering research and clinical application. Thus, an effective 
way is necessary to produce a sufficient amount of the BMP-2 
protein. With the advance in plant biotechnology, transgenic 
plants have been targeted as a bioreactor to produce desired 
recombinant proteins. Therefore, the expression of the 
recombinant human BMP-2 gene (rhBMP-2) was studied in 
tobacco plants using GUS as a reporter gene. The difference 
between expression levels in root, stem, and leaf tissues were 
analyzed by a GUS activity assay, semi-quantitative RT-PCR, and 
Western blotting. The results indicated that the expression levels 
of fusion protein in root and stem tissues were significantly higher 
than those in leaf tissues.11 
Prokaryotic expression systems of rhBMP-2 have several 
advantages over other systems. The prokaryotic system allows 
one to obtain large quantities of recombinant proteins in a short 
time. A simple and inexpensive bacterial cell culture facilitates the 
use of these microorganisms.12 Zhang et al., (2010) showed that 
BMP-2 genes can be cloned from MG-63 cells by RT-PCR and 
rhBMP-2 can be expressed in E. coli. In this study, BMP-2 genes 
were cloned into a pET30 (a) vector and transformed into E. coli 
BL21 and rhBMP-2, which was expressed as inclusion bodies. 
They tried to optimize the conditions for the prokaryotic 
expression system to improve the soluble expression of rhBMP-2, 
including the culture temperature, carbon source, IPTG 
concentration, and culture temperature. However, they failed to 
obtain any soluble rhBMP-2. Therefore, the inclusion bodies were 
harvested and solubilized in the solubilization buffer and the 
denatured rhBMP-2 was purified by Ni-NTA column.13 
In general, the production of recombinant proteins for 
therapeutic purposes is greatly considered in recent years. 
Recombinant BMP-2 expression and purification from bacterial 
expression systems may be of great interest because of the 
osteoinductive properties of this protein. 
However, because the production of recombinant proteins 
requires an expression system, the choice of the expression system 
becomes the determinant factor for efficiency and quality of the 
final BMP molecules produced. The pGEM-b1 vector and E. coli 
Rosetta strain were not employed for BMP-2 cloning in previous 
investigations. Therefore, this method may be a useful approach 
to reduce the challenges ahead of the optimization of BMP-2 
production. It seems that E. coli Rosetta is a proper candidate for 
the expression of rhBMP-2 in a short time, using a simple and 
inexpensive method. 
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